Literature DB >> 16133038

Angiotensin blockade in children with chronic glomerulonephritis and heavy proteinuria.

Lavjay Butani1.   

Abstract

Patients with chronic proteinuric nephropathies are at high risk of developing progressive renal insufficiency. There are limited controlled data on the efficacy of potentially toxic immunosuppressive therapies for many of these diseases such as immunoglobulin A nephropathy and idiopathic membranoproliferative glomerulonephritis. This limitation has not deterred healthcare providers from using such agents based on anecdotal experience. We report our experience taking care of three children with heavy proteinuria from chronic glomerular diseases. All were treated with a combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers without concomitant immunosuppression. All went into complete remission soon after starting therapy, allowing corticosteroid avoidance. The purpose of this report is to make healthcare professionals more aware of the potential success that can be achieved with this relatively nontoxic drug regimen. Larger controlled clinical trials using this strategy are needed to better evaluate the efficacy and safety of this approach in children with glomerular diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133038     DOI: 10.1007/s00467-005-2031-5

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  10 in total

1.  Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy.

Authors:  Rakesh Bhattacharjee; G Filler
Journal:  Pediatr Nephrol       Date:  2002-04       Impact factor: 3.714

2.  The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises.

Authors:  Arrigo Schieppati; Giuseppe Remuzzi
Journal:  Kidney Int       Date:  2003-12       Impact factor: 10.612

3.  Remission of membranoproliferative nephritis with angiotensin converting enzyme inhibition and receptor blockade.

Authors:  Lavjay Butani
Journal:  Pediatr Nephrol       Date:  2003-09-17       Impact factor: 3.714

4.  Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.

Authors:  D Russo; R Minutolo; A Pisani; R Esposito; G Signoriello; M Andreucci; M M Balletta
Journal:  Am J Kidney Dis       Date:  2001-07       Impact factor: 8.860

5.  Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone--a report of the International Study of Kidney Disease in Children.

Authors:  P Tarshish; J Bernstein; J N Tobin; C M Edelmann
Journal:  Pediatr Nephrol       Date:  1992-03       Impact factor: 3.714

Review 6.  Comparative effects of ACE inhibition and angiotensin II receptor blockade in the prevention of renal damage.

Authors:  Saulo Klahr; Jeremiah Morrissey
Journal:  Kidney Int Suppl       Date:  2002-12       Impact factor: 10.545

7.  Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.

Authors:  Hiroshi Tanaka; Koichi Suzuki; Tohru Nakahata; Koji Tsugawa; Yuki Konno; Kazushi Tsuruga; Etsuro Ito; Shinobu Waga
Journal:  Pediatr Int       Date:  2004-10       Impact factor: 1.524

8.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

9.  Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial.

Authors:  Manuel Praga; Eduardo Gutiérrez; Ester González; Enrique Morales; Eduardo Hernández
Journal:  J Am Soc Nephrol       Date:  2003-06       Impact factor: 10.121

10.  Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency.

Authors:  S Giri; S K Mahajan; R Sen; A Sharma
Journal:  J Assoc Physicians India       Date:  2002-10
  10 in total
  3 in total

Review 1.  Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents.

Authors:  Siegtraut Dorothea Herder; Ernst Weber; Almuth Winkemann; Christoph Herder; Hartmut Morck
Journal:  Pediatr Nephrol       Date:  2010-05       Impact factor: 3.714

Review 2.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

3.  Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series.

Authors:  Giuseppina Spartà; Ariana Gaspert; Thomas J Neuhaus; Marcus Weitz; Nilufar Mohebbi; Urs Odermatt; Peter F Zipfel; Carsten Bergmann; Guido F Laube
Journal:  Clin Kidney J       Date:  2018-02-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.